Table 3.
Groups | Dosage (mg/kg) | Increase of body weight (g) | Tumor weight (g) | Inhibitory rate (%) | Thymus index (mg/g) | Spleen index (mg/g) |
---|---|---|---|---|---|---|
Normal | — | 5.44 | — | — | 1.43 ± 0.19 | 3.63 ± 0.30 |
Model | — | 7.11 | 1.79 ± 0.35 | — | 1.94 ± 0.16 | 6.89 ± 0.54 |
Positive | 25 | 4.37 | 0.50 ± 0.11** | 72.06 | 1.24 ± 0.20** | 4.40 ± 0.40** |
ARG | 40 | 6.30 | 1.32 ± 0.34**,## | 26.26 | 1.54 ± 0.26**,# | 5.71 ± 0.50 **,## |
ARG-V | 20 | 5.59 | 1.03 ± 0.19**,##,a | 42.46 | 1.75 ± 0.24*,## | 4.80 ± 0.42**,#,aa |
ARG-V | 40 | 4.94 | 0.55 ± 0.15**,aa | 69.27 | 1.87 ± 0.21##,aa | 4.53 ± 0.57 **,aa |
ARG-V | 80 | 5.11 | 0.66 ± 0.17**,#,aa | 63.13 | 1.77 ± 0.18*,##,a | 5.34 ± 0.50**,## |
Values are expressed as mean ± SD (n = 8).
**P < 0.01 as compared with the model group.#P < 0.05 as compared with the Positive group.
##P < 0.01 as compared with the Positive group.aP < 0.05 as compared with the ARG group.
aaP < 0.01 as compared with the ARG group.